Brokerages Set Guardant Health, Inc. (NASDAQ:GH) Price Target at $77.14

Guardant Health, Inc. (NASDAQ:GH) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-four brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and twenty-three have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $80.8571.

Several equities analysts have weighed in on GH shares. Citigroup raised their price target on Guardant Health from $65.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Canaccord Genuity Group set a $100.00 target price on Guardant Health in a research report on Thursday, October 30th. Piper Sandler raised their target price on shares of Guardant Health from $60.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Mizuho set a $100.00 price target on shares of Guardant Health in a research report on Thursday, October 30th. Finally, Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday, October 30th.

Guardant Health Stock Performance

Shares of NASDAQ GH opened at $102.02 on Monday. The company has a market cap of $12.86 billion, a P/E ratio of -31.78 and a beta of 1.58. Guardant Health has a 52-week low of $29.91 and a 52-week high of $112.43. The firm’s fifty day moving average is $84.67 and its two-hundred day moving average is $63.43.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.09. During the same quarter in the prior year, the company posted ($0.88) EPS. The business’s quarterly revenue was up 38.5% compared to the same quarter last year. As a group, analysts forecast that Guardant Health will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In related news, insider Terilyn J. Monroe sold 55,167 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $105.97, for a total value of $5,846,046.99. Following the completion of the transaction, the insider owned 20,920 shares of the company’s stock, valued at approximately $2,216,892.40. This trade represents a 72.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Helmy Eltoukhy sold 300,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 368,228 shares of company stock worth $24,835,525 in the last 90 days. 6.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Sound Income Strategies LLC bought a new stake in shares of Guardant Health during the 3rd quarter worth approximately $38,000. IFP Advisors Inc increased its stake in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock worth $33,000 after purchasing an additional 334 shares during the period. Signaturefd LLC increased its stake in Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock worth $33,000 after purchasing an additional 213 shares during the period. Allworth Financial LP lifted its position in shares of Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the last quarter. Finally, Optiver Holding B.V. boosted its stake in shares of Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock valued at $48,000 after purchasing an additional 465 shares during the period. Institutional investors own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.